Hair loss in women is more common than most people realize, and more treatable than most women are told. Eros MD provides physician-supervised evaluation and treatment tailored specifically to the female hair loss picture.
about women's hair loss
Hair loss in women is significantly underrecognized. It affects an estimated 40 percent of women by age 50, yet receives far less clinical attention than male pattern baldness, and far less culturally acknowledged space for the distress it causes.
The most common cause of hair loss in women is female androgenetic alopecia, also called female pattern hair loss (FPHL). Like its male counterpart, it is driven by a combination of genetic predisposition and androgen sensitivity in the hair follicles. In women, however, the pattern differs: rather than the receding hairline and crown baldness common in men, FPHL typically presents as diffuse thinning across the top and crown of the scalp, with the frontal hairline often preserved.
Other common causes of hair loss in women include telogen effluvium (diffuse shedding triggered by physical or emotional stress, illness, hormonal changes, or nutritional deficiencies), hormonal shifts from pregnancy, postpartum recovery, perimenopause, or thyroid dysfunction, iron deficiency or other nutritional gaps, and scarring or inflammatory conditions of the scalp. Physician evaluation is essential to distinguish between these causes. Treatment differs significantly depending on the underlying driver.
Eros MD providers approach women's hair loss with a full diagnostic lens: a comprehensive intake covering your hair loss history, hormonal context, health history, medications, and nutritional status, before recommending any treatment.
treatment options
Treatment selection for women's hair loss depends on the underlying cause, hormonal status, pregnancy status, and individual health profile. Options available through Eros MD include minoxidil (topical or oral), spironolactone for androgen-driven patterns, and addressing underlying nutritional or thyroid contributors.
2 percent topical minoxidil is FDA-approved specifically for women with female pattern hair loss. The 5 percent concentration is also used in women under physician supervision. Minoxidil extends the hair growth phase and increases blood flow to follicles, stimulating growth and reducing shedding.
Low-dose oral minoxidil is increasingly used in women under physician supervision, with better adherence than twice-daily topical application. Used off-label for hair loss, prescribed after physician evaluation.
An oral medication with well-established off-label use for androgen-driven hair loss in women. Blocks androgen receptors in the hair follicle, reducing the hormonal signal that drives miniaturization in androgenetic alopecia. Not appropriate during pregnancy or for women planning pregnancy. Requires reliable contraception.
Iron, thyroid, and nutritional labs ordered through your local lab network when clinically indicated. For perimenopausal women, hair loss often responds best when paired with HRT. We coordinate across programs.
important note on finasteride
Finasteride is generally not recommended for premenopausal women or women who may become pregnant due to the risk of birth defects in male fetuses. It is sometimes prescribed off-label by physicians in postmenopausal women under carefully managed conditions. The default position at Eros MD for women of childbearing potential is that finasteride is not appropriate.
All treatment decisions for women's hair loss are made by a licensed physician after a full evaluation. Treatment selection depends on your hair loss type, cause, hormonal status, and any contraindications specific to your health profile.
A comprehensive intake covers hair loss pattern, duration, hormonal context, health history, medications, and nutritional status. Labs are ordered when clinically indicated.
Different patterns (diffuse, patterned, specific regions) signal different causes. Your provider designs a protocol around what your evaluation actually reveals.
For perimenopausal or thyroid-driven hair loss, the treatment sits across multiple programs. Eros MD coordinates with our women's energy and hormone support, weight loss, and other relevant programs.
Questions worth asking
The most common cause is female androgenetic alopecia (female pattern hair loss), driven by genetic predisposition and androgen sensitivity in the hair follicles. Other causes include telogen effluvium (stress or illness-triggered shedding), hormonal changes from pregnancy, postpartum recovery, perimenopause, thyroid dysfunction, and nutritional deficiencies. Physician evaluation is required to identify the correct cause.
Yes. 2 percent topical minoxidil is FDA-approved specifically for women with female pattern hair loss. The 5 percent topical and low-dose oral formulations are used off-label in women under physician supervision. Minoxidil should not be used during pregnancy or breastfeeding.
Finasteride is generally not recommended for women of childbearing potential due to the risk of birth defects in male fetuses. It is occasionally prescribed off-label in postmenopausal women under carefully managed conditions. Eros MD does not prescribe finasteride to premenopausal women for hair loss.
Spironolactone is an oral anti-androgen medication prescribed off-label for female androgenetic alopecia. It blocks androgen receptors in the hair follicle, reducing the hormonal signal that drives female pattern hair loss. It is one of the most effective treatments for androgen-driven hair loss in women and is widely used by dermatologists for this purpose.
Most women begin to notice a reduction in shedding within 2 to 3 months of starting treatment. Visible improvement in hair thickness and density typically becomes noticeable at 4 to 6 months. Maximum results generally require 12 months of consistent treatment.
Eros MD evaluates and treats the most common forms of women's hair loss: female androgenetic alopecia, telogen effluvium, and hormonally driven shedding. Scarring alopecias and inflammatory scalp conditions may require in-person dermatological assessment and are outside the scope of telehealth treatment. Your provider will identify if an in-person referral is needed.